High expression reduces an antibody response after neonatal gene therapy with B domain‐deleted human factor VIII in mice

Hematology: Basic Principles and Practice

Toby Simon · Transfusion · 2001 · 744 citations

Life Sciences, Immunology, Pathobiology +17

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study

Samantha C. Gouw, Johanna G. van der Bom, H. Marijke van den Berg · Blood · 2007 · 487 citations

Medicine, Hematology, Pharmacotherapy +14

A large region (approximately equal to 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity.

J J Toole, Debra D. Pittman, Elizabeth C. Orr et al. · Proceedings of the National Academy of Sciences · 1986 · 314 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +15

Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII

DD Pittman, EM Alderman, KN Tomkinson et al. · Blood · 1993 · 264 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +9

Environmental risk factors for inhibitor development in children with haemophilia A: a case–control study

Elena Santagostino, Maria Elisa Mancuso, Angiola Rocino et al. · British Journal of Haematology · 2005 · 192 citations · Full text

Medicine, Genetics, Pediatrics +10